Evidence map›Paper›PMID 30541509›Full record

ArticleBMC public health2018

Acute flaccid paralysis (AFP) surveillance intensification for polio certification in Kaduna state, Nigeria: lessons learnt, 2015-2016.

Gregory C Umeh, Faisal Shuaib, Audu Musa, Sisay G Tegegne, Fiona Braka, Pascal Mkanda, Richard Banda, Usman Adamu, Terna I Nomhwange, Eyiotoyo Arenyeka and 7 more

Abstract read
In one paragraph

Article in BMC public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Gregory C UmehWorld Health Organization, Country Representative Office, Abuja, Nigeria. umehg@who.int.
Faisal ShuaibNational Primary Health Care Development Agency, Abuja, Nigeria.
Audu MusaWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Sisay G TegegneWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Fiona BrakaWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Pascal MkandaWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Richard BandaWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Usman AdamuNational Primary Health Care Development Agency, Abuja, Nigeria.
Terna I NomhwangeWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Eyiotoyo ArenyekaWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Semeeh A OmolekeWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Ticha M JohnsonWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Kehinde CraigWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Ibrahim IdrisWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Hadiza IyalWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Ishaku G SamboWorld Health Organization, Country Representative Office, Abuja, Nigeria.
Peter NsubugaGlobal Public Health Solutions, Atlanta, GA, USA.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundNigeria has made remarkable progress in its current efforts to interrupt wild poliovirus transmission despite the re-emergence of wild poliovirus in 2016. The gains made in Nigeria have been achieved through concerted efforts by governments at all levels, traditional leaders, health workers, caregivers, and development partners. The efforts have involved an elaborate plan, coordination, and effective implementation of routine immunization services, supplemental immunization activities, and acute flaccid paralysis (AFP) surveillance.

methodsWe conducted the following activities to strengthen AFP surveillance in Kaduna state: a monetary reward for all AFP cases reported by health workers or community informants and verified as "true" AFP by a World Health Organization (WHO) cluster coordinator; training and sensitization of surveillance officers, clinicians, and community informants; recruitment of more personnel and expansion of the surveillance network; and the involvement of special populations (nomadic, hard-to-reach, and border communities) and caregivers in stool sample collection. The paired t test was used to evaluate the impact of the different initiatives implemented in Kaduna state to intensify AFP surveillance in 2016.

resultsThere was increased annualized non-polio AFP rate (ANPAFPR) in 21 out of 23 Local Government Areas (LGAs) of Kaduna state 6 months after implementation of different initiatives to intensify AFP surveillance. The AFP reported by the special population increased in 15 out of 23 LGAs. Statistical analyses of mean scores of ANPAFPR before and after the interventions using the paired t test revealed a significant difference in mean scores: mean = 19.7 (standard deviation (SD) = 16.1) per 100,000 < 15 years old in July-December 2015, compared with 38.0 (SD = 21.6) per 100,000 < 15 years old in January-June 2016 (p < 0.05). Likewise, analysis of silent wards using the paired t test showed a significant difference in mean scores: mean = 4.0 (SD = 2.1) in July-December 2015 compared with 2.4 (SD = 1.8) in January-June 2016 (p < 0.05).

conclusionThe different initiatives implemented in 23 LGAs of Kaduna state to intensify AFP surveillance may be responsible for the significant improvement in the AFP surveillance performance indicators in 2016.

Indexed as

Population SurveillanceAcute DiseaseCertificationChildHumansMuscle HypotoniaNigeriaParalysisPoliomyelitisAcute flaccid paralysisKaduna statePolio certification

Identifiers

PMID30541509
PMCPMC6291918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.